Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

• প্রধান লেখক: Inja Waldhauer (লেখক), Valeria Gonzalez-Nicolini (লেখক), Anne Freimoser-Grundschober (লেখক), Tapan K Nayak (লেখক), Linda Fahrni (লেখক), Ralf J. Hosse (লেখক), Danny Gerrits (লেখক), Edwin J. W. Geven (লেখক), Johannes Sam (লেখক), Sabine Lang (লেখক), Esther Bommer (লেখক), Virginie Steinhart (লেখক), Elisabeth Husar (লেখক), Sara Colombetti (লেখক), Erwin Van Puijenbroek (লেখক), Markus Neubauer (লেখক), J. Mark Cline (লেখক), Pradeep K. Garg (লেখক), Gregory Dugan (লেখক), Federica Cavallo (লেখক), Gonzalo Acuna (লেখক), Jehad Charo (লেখক), Volker Teichgräber (লেখক), Stefan Evers (লেখক), Otto C. Boerman (লেখক), Marina Bacac (লেখক), Ekkehard Moessner (লেখক), Pablo Umaña (লেখক), Christian Klein (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα. Here, we investigated the immunostimulatory properties of F...